{"id":52935,"date":"2023-01-16T13:02:25","date_gmt":"2023-01-16T12:02:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/"},"modified":"2023-01-16T13:02:25","modified_gmt":"2023-01-16T12:02:25","slug":"2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/","title":{"rendered":"2022 Hidradenitis Suppurativa (HS) Epidemiology Forecast to 2032: The US has the Largest Number of Affected People &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5010962\/hidradenitis-suppurativa-hs-epidemiology?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=gsgcvr&amp;utm_campaign=1807952+-+2022+Hidradenitis+Suppurativa+(HS)+Epidemiology+Forecast+to+2032%3A+The+US+has+the+Largest+Number+of+Affected+People&amp;utm_exec=jamu273prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Hidradenitis Suppurativa (HS) &#8211; Epidemiology Forecast &#8211; 2032&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230116005295\/en\/1686462\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230116005295\/en\/1686462\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThis report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU-5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.\n<\/p>\n<p>\n<strong>Geography Covered<\/strong>\n<\/p>\n<ul>\n<li>\nThe United States\n<\/li>\n<li>\nThe EU-5\n<\/li>\n<li>\nJapan\n<\/li>\n<\/ul>\n<p>\n<strong>Study Period:<\/strong> 2019-2032\n<\/p>\n<p>\n<strong>Hidradenitis Suppurativa Disease Understanding<\/strong>\n<\/p>\n<p>\n<strong>Hidradenitis Suppurativa Overview<\/strong>\n<\/p>\n<p>\nAccording to the National Organization of Rare Disorders, hidradenitis Suppurativa is a chronic condition characterized by swollen, painful lesions, occurring in the armpit, groin, anal and breast regions. It is painful and long-term skin condition causing abscesses and scarring on the skin.\n<\/p>\n<p>\nAffected patients may present with acute abscesses, but the condition often progresses to a chronic state with persistent pain, sinus tract fistula formation, and scarring. Although foreign body type granulomas are a common finding in HS, the presence of discrete epithelioid granulomas in the dermis away from the site of active inflammation is unusual and should alert the pathologist to the possibility of a systemic granulomatous disease like Crohn&#8217;s disease (CD) or sarcoidosis.\n<\/p>\n<p>\nThe longstanding disease can result in fibrosis, dermal contractures, significant scarring, the formation of fistulae, and rarely malignant transformation to squamous cell carcinoma.\n<\/p>\n<p>\nThe diagnosis is primarily clinical, based on symptoms reported by the patient and signs observed by the physician. No pathognomonic test exists, and biopsy is rarely required, especially in well-developed lesions.\n<\/p>\n<p>\n<strong>Hidradenitis Suppurativa Epidemiology<\/strong>\n<\/p>\n<p>\nThe disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent population of Hidradenitis Suppurativa, gender-specific prevalent population of Hidradenitis Suppurativa, age-specific prevalent population of Hidradenitis Suppurativa, stage-specific population of Hidradenitis Suppurativa, in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2019 to 2032.\n<\/p>\n<p>\n<strong>Key Findings<\/strong>\n<\/p>\n<p>\nThis section provides glimpse of the Hidradenitis Suppurativa epidemiology in the 7MM\n<\/p>\n<p>\n<strong>Country Wise- Hidradenitis Suppurativa Epidemiology<\/strong>\n<\/p>\n<ul>\n<li>\nThe epidemiology segment also provides the Hidradenitis Suppurativa epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.\n<\/li>\n<li>\nThe total diagnosed prevalent population of Hidradenitis Suppurativa in the 7MM comprised of 1,239,695 cases in 2021 and are projected to increase during the forecast period.\n<\/li>\n<li>\nThe total diagnosed prevalent population of Hidradenitis Suppurativa in the United States is 572,057 in 2021.\n<\/li>\n<li>\nThe United States contributed to the largest prevalent population of Hidradenitis Suppurativa, in 7MM in 2021.\n<\/li>\n<li>\nAmong the EU-5 countries, Germany accounted for the highest number of Hidradenitis Suppurativa cases, whereas Spain accounted for the lowest cases in 2021.\n<\/li>\n<li>\nIn Japan, the total diagnosed prevalent population of Hidradenitis Suppurativa was 89,917 in 2021 and is anticipated to rise during the forecast period.\n<\/li>\n<li>\nIn 2021, males and females accounted for 143,014 and 429,043 cases respectively in the United States.\n<\/li>\n<\/ul>\n<p>\n<strong>Scope of the Report<\/strong>\n<\/p>\n<ul>\n<li>\nThe report covers the descriptive overview of Hidradenitis Suppurativa, explaining its causes, signs and symptoms, pathogenesis and diagnosis.\n<\/li>\n<li>\nComprehensive insight has been provided into the Hidradenitis Suppurativa epidemiology and treatment.\n<\/li>\n<li>\nThe report provides insight about the historical and forecasted patient pool of Hidradenitis Suppurativa in seven major markets covering the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.\n<\/li>\n<li>\nThe report helps to recognize the growth opportunities in the 7MM with respect to the patient population.\n<\/li>\n<li>\nA detailed review of Hidradenitis Suppurativa epidemiology forecast is included in the report, covering the 7MM drug outreach.\n<\/li>\n<li>\nThe report provides an edge while developing business strategies, by understanding epidemiological trends.\n<\/li>\n<\/ul>\n<p>\n<strong>Key Questions<\/strong>\n<\/p>\n<ul>\n<li>\nWhat is the disease risk, burden and unmet needs of Hidradenitis Suppurativa?\n<\/li>\n<li>\nWhat is the historical Hidradenitis Suppurativa patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK) and Japan?\n<\/li>\n<li>\nWhat would be the forecasted patient pool of Hidradenitis Suppurativa at the 7MM level?\n<\/li>\n<li>\nWhat will be the growth opportunities across the 7MM with respect to the patient population pertaining to Hidradenitis Suppurativa?\n<\/li>\n<li>\nOut of the above-mentioned countries, which country would have the highest prevalent population of Hidradenitis Suppurativa during the study period (2019-2032)?\n<\/li>\n<li>\nAt what CAGR the population is expected to grow across the 7MM during the study period (2019-2032)?\n<\/li>\n<\/ul>\n<p>\n<strong>Reasons to Buy<\/strong>\n<\/p>\n<ul>\n<li>\nThe report will help in developing business strategies by understanding trends shaping and driving the Hidradenitis Suppurativa.\n<\/li>\n<li>\nTo understand the future market competition in the Hidradenitis Suppurativa market and Insightful review of the key market drivers and barriers.\n<\/li>\n<li>\nQuantify patient populations in the global Hidradenitis Suppurativa market to improve product design, pricing, and launch plans\n<\/li>\n<li>\nOrganize sales and marketing efforts by identifying the best opportunities for Hidradenitis Suppurativa in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.\n<\/li>\n<li>\nThe Hidradenitis Suppurativa Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5010962\/hidradenitis-suppurativa-hs-epidemiology?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=gsgcvr&amp;utm_campaign=1807952+-+2022+Hidradenitis+Suppurativa+(HS)+Epidemiology+Forecast+to+2032%3A+The+US+has+the+Largest+Number+of+Affected+People&amp;utm_exec=jamu273prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/d3a86o<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#x69;&#x6c;&#116;&#x6f;&#x3a;&#112;&#x72;&#x65;&#115;&#x73;&#x40;r&#x65;&#x73;e&#x61;&#114;c&#x68;&#97;n&#x64;&#109;a&#x72;&#107;e&#x74;&#115;&#46;&#x63;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">&#112;&#x72;e&#x73;&#x73;&#64;&#x72;e&#x73;&#x65;&#97;&#x72;c&#x68;&#x61;&#110;&#x64;m&#x61;&#x72;&#107;&#x65;t&#x73;&#x2e;&#99;&#x6f;m<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Hidradenitis Suppurativa (HS) &#8211; Epidemiology Forecast &#8211; 2032&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU-5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. Geography Covered The United States The EU-5 Japan Study Period: 2019-2032 &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52935","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>2022 Hidradenitis Suppurativa (HS) Epidemiology Forecast to 2032: The US has the Largest Number of Affected People - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"2022 Hidradenitis Suppurativa (HS) Epidemiology Forecast to 2032: The US has the Largest Number of Affected People - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Hidradenitis Suppurativa (HS) &#8211; Epidemiology Forecast &#8211; 2032&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU-5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. Geography Covered The United States The EU-5 Japan Study Period: 2019-2032 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-16T12:02:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230116005295\/en\/1686462\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"2022 Hidradenitis Suppurativa (HS) Epidemiology Forecast to 2032: The US has the Largest Number of Affected People &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2023-01-16T12:02:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\\\/\"},\"wordCount\":876,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230116005295\\\/en\\\/1686462\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\\\/\",\"name\":\"2022 Hidradenitis Suppurativa (HS) Epidemiology Forecast to 2032: The US has the Largest Number of Affected People - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230116005295\\\/en\\\/1686462\\\/21\\\/logo.jpg\",\"datePublished\":\"2023-01-16T12:02:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230116005295\\\/en\\\/1686462\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230116005295\\\/en\\\/1686462\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"2022 Hidradenitis Suppurativa (HS) Epidemiology Forecast to 2032: The US has the Largest Number of Affected People &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"2022 Hidradenitis Suppurativa (HS) Epidemiology Forecast to 2032: The US has the Largest Number of Affected People - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"2022 Hidradenitis Suppurativa (HS) Epidemiology Forecast to 2032: The US has the Largest Number of Affected People - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Hidradenitis Suppurativa (HS) &#8211; Epidemiology Forecast &#8211; 2032&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU-5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. Geography Covered The United States The EU-5 Japan Study Period: 2019-2032 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-16T12:02:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230116005295\/en\/1686462\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"2022 Hidradenitis Suppurativa (HS) Epidemiology Forecast to 2032: The US has the Largest Number of Affected People &#8211; ResearchAndMarkets.com","datePublished":"2023-01-16T12:02:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/"},"wordCount":876,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230116005295\/en\/1686462\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/","name":"2022 Hidradenitis Suppurativa (HS) Epidemiology Forecast to 2032: The US has the Largest Number of Affected People - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230116005295\/en\/1686462\/21\/logo.jpg","datePublished":"2023-01-16T12:02:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230116005295\/en\/1686462\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230116005295\/en\/1686462\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/2022-hidradenitis-suppurativa-hs-epidemiology-forecast-to-2032-the-us-has-the-largest-number-of-affected-people-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"2022 Hidradenitis Suppurativa (HS) Epidemiology Forecast to 2032: The US has the Largest Number of Affected People &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52935"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52935\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52935"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52935"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}